SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Dublin, March 08, 2017 -- Research and Markets has announced the addition of the "The World Market for Personalized Medicine Tests for Cancer" report to their offering.
Personalized Medicine Tests for Cancer, provides an authoritative look at the market for companion and personalized medicine testing for cancer. The report includes a market size and forecast for personalized medicine testing by geography (US, EU, ROW). Company profiles are included and products are identified by status (on the market, in development)
Key Topics Covered:
Chapter One Executive Summary
- The Scourge of Cancer
- Definitions of Companion Diagnostics and Cancer Diagnostics
- Types of Tests Included
- Marketing Personalized Medicine-Based Cancer Tests
- Market
- Point of View
Chapter Two Introduction
- Cancer Treatments
- Cancer Risk Assessment
- Cancer Screening
- Cancer Monitoring
- Prognosis Assessment
- Technologies Used
- Immunoassays
- Immunohistochemistry (IHC)
- Flow Cytometry
- In Situ Hybridization
- Nucleic Acid Amplification Technologies
- Analysis of Gene Expression Patterns (Gene Signatures)
- Microarrays
- Sequencing Technologies
- Mass Spectrometry
- Liquid Biopsies
- Information Technology
- Test Targets
- HER2 Overexspression
- EGFR
- KRAS Mutations
- BRAF Mutations
- UGT1A1 Genetic Variants
- 5-Flurouracil Therapy
- PIK3CA Mutations
- KIF6 Mutations
- ALK Mutations
Chapter Three Market Analysis
- Products on the Market
- Market Analysis
- Drivers
- Diagnostic Companies and Pharmaceutical Companies
- Growth by Geography
Chapter Four Company Profiles.
- 20/20 GeneSystems, Inc.
- Abbott Laboratories
- ACT Genomics Co., Ltd.
- Adaptive Biotechnologies Corporation
- Admera Health (A GENEWIZ Company)
- Agena Bioscience Inc.
- Agendia NV
- Amoy Diagnostics Co., Ltd.
- ARKRAY, Inc.
- Biocartis
- bioMérieux SA
- Cepheid (Danaher)
- Genomic Health, Inc.
- Genoptix (A Novartis Company)
- Luminex Corporation
- Myriad Genetics, Inc.
- Qiagen N.V.
- QuanDx Inc.
- Quest Diagnostics
- Qvella Corporation
- RiboMed Biotechnologies, Inc.
- Roche
- Siemens Healthcare
- Symbiodx
- Theranostics Health Inc. (Acquired by Avant Diagnostics, Inc.)
- Thermo Fisher Scientific, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/778jp3/the_world_market
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Healthcare Services, Genomics, Diagnostics, Oncology Drugs
